BURDEN, RISK FACTORS AND PREVENTION OF RESPIRATORY INFECTIONS AND INFECTIOUS DISEASES IN CHILDREN
Associate Professor Hannah Moore OAM
Program Head, Infection and Vaccines,
The Kids Research Institute Australia &
Associate Professor at the School of Population Health, Curtin University
Western Australia
RESEARCHER PROFILE (Filmed in Perth, Western Australia | December 2024)
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
Her passion for research involves using population-based data to investigate how to recognise, prevent and reduce serious respiratory and other infectious diseases in children through estimating burden of disease and evaluating the effectiveness of vaccination programs. She has developed expertise in the epidemiology of Respiratory Syncytial Virus (RSV) in young children, where her research was pivotal in WA Governments’ decision to establish the first and most comprehensive RSV infant immunisation program in the nation. Raising awareness of RSV, understanding community burden and evaluating the impact of prevention measures is now a major focus of her research program. She has previously contributed to state and national influenza vaccination policy.
In 2020 A/Prof Moore joined the Strep A Vaccine Global Consortium (SAVAC) to increase knowledge and awareness of the global burden of Group A Streptococcal diseases. She now holds an activity lead position in the US$11M-funded SAVAC 2.0.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.
Editor’s note: At the time of recording in September 2024, A/Prof Hannah Moore makes reference to needing a national RSV immunisation program. Efforts by her and others in campaigning were successful and in November 2024 the Australian National Immunisation Program was updated to include RSV from 2025. https://www.health.gov.au/news/national-immunisation-program-update-rsv-vaccine#:~:text=The%20inclusion%20of%20the%20RSV,announced%20as%20soon%20as%20possible.
https://orcid.org/0000-0003-4920-9991
-
Engineering bacteria to detect colorectal cancer cells
An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
